Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

NCT04526899 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT04526899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04526899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
Lead sponsor
BioNTech SE
Phase
Phase 2
Overall status
Completed
Start date
May 19, 2021
Completion date
November 24, 2025
Enrollment
184 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iii, melanoma stage iv, unresectable melanoma